Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib and Trastuzumab in Advanced Breast Cancer
NCT00054470Phase 2Withdrawn
- Sponsor
- UT Health San Antonio
- Start
- Dec 2002
- Primary completion
- Jan 2003
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of tipifarnib in breast cancer, sponsored by UT Health San Antonio. Primary endpoints: Antitumor activity and Safety and tolerability. Planned start Dec 2002; status: withdrawn.
02
Drugs
tipifarnib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00054470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054470.